Similar Median OS Between Ripretinib versus Sunitinib in Patients with Advanced GIST While Safety More Favourable for Ripretinib By Ogkologos - June 2, 2025 491 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the final overall survival and updated safety analysis of the INTRIGUE study Source RELATED ARTICLESMORE FROM AUTHOR ESMO’s Special Consultative Status with United Nations Economic and Social Council (UN ECOSOC) Confirmed Until 2028 EMA Recommends Extension of Indications for Selumetinib ESMO Calls for Urgent Changes to the in Vitro Diagnostic Medical Devices Regulation (IVDR) in Order to Safeguard Cancer Research in Europe MOST POPULAR Volunteering with Pride: Brett’s award-winning involvement with Cancer Research UK June 15, 2023 Greater Severity of Adverse Events in Women Across Multiple Anticancer Treatment... February 11, 2022 The Horror Story Of What Can Happen When You Don’t Pay... September 16, 2019 Fostering Black leadership in cancer research July 20, 2023 Load more HOT NEWS 30-Year-Old Mom of 7 With Terminal Breast Cancer Is Gifted Dream... NCI’s Rare Cancer Clinics: Engaging Patients and Fostering Collaboration How Early Cancer Detection and Diagnosis Saved My Life Twice: A... FDA Grants Accelerated Approval to fam-Trastuzumab Deruxtecan-nxki for Unresectable or Metastatic...
